Shattuck Labs, Inc. (NASDAQ:STTK) Receives Average Rating of “Hold” from Brokerages

Shattuck Labs, Inc. (NASDAQ:STTK) has received an average recommendation of “Hold” from the seven analysts that are currently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and four have given a buy recommendation to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $6.20.

A number of research firms have recently commented on STTK. Piper Sandler started coverage on shares of Shattuck Labs in a research note on Wednesday, January 28th. They set an “overweight” rating and a $15.00 price objective for the company. HC Wainwright upgraded shares of Shattuck Labs from a “neutral” rating to a “buy” rating and set a $6.00 target price for the company in a report on Monday, December 1st. Citigroup increased their price target on shares of Shattuck Labs from $2.00 to $4.00 and gave the stock a “neutral” rating in a research note on Tuesday, January 6th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Shattuck Labs in a report on Thursday, January 22nd.

Shattuck Labs Stock Performance

Shattuck Labs stock traded down $0.16 during trading on Thursday, hitting $3.93. The company’s stock had a trading volume of 59,073 shares, compared to its average volume of 729,902. The stock’s fifty day moving average is $3.79 and its 200 day moving average is $2.44. Shattuck Labs has a 1-year low of $0.69 and a 1-year high of $4.89. The stock has a market capitalization of $248.63 million, a price-to-earnings ratio of -3.83 and a beta of 1.52.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Turtle Creek Wealth Advisors LLC acquired a new position in shares of Shattuck Labs during the 3rd quarter valued at $29,000. Virtu Financial LLC acquired a new position in shares of Shattuck Labs during the third quarter worth $38,000. AQR Capital Management LLC boosted its position in Shattuck Labs by 265.4% in the 1st quarter. AQR Capital Management LLC now owns 43,169 shares of the company’s stock valued at $41,000 after buying an additional 31,355 shares during the last quarter. Qube Research & Technologies Ltd acquired a new stake in shares of Shattuck Labs during the second quarter valued at about $44,000. Finally, Squarepoint Ops LLC bought a new position in Shattuck Labs during the 3rd quarter valued at $46,000. 58.74% of the stock is owned by institutional investors and hedge funds.

About Shattuck Labs

Shattuck Labs, Inc (NASDAQ: STTK) is a clinical‐stage biotechnology company headquartered in Cambridge, Massachusetts. The company is focused on developing immunotherapeutic vaccines to prevent and treat substance use disorders, with an initial emphasis on opioids. Shattuck Labs employs a proprietary hapten‐carrier conjugate technology designed to generate high‐affinity drug‐specific antibodies that sequester target molecules in the bloodstream and reduce their passage across the blood‐brain barrier.

The company’s lead program targets fentanyl, a synthetic opioid responsible for a significant proportion of overdose fatalities.